Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
HEALTH ODYSSEY - 88th Canadian Paediatric Society Annual Conference
Solving Common Feeding Difficulties in Paediatrics: A Practical Approach
Québec City, Québec / June 15-18, 2011
Québec City – Feeding difficulties in infants and children are extremely common and physicians need to identify specific types of feeding difficulties in order to counsel parents accordingly. Once identified, resolution of the...
PRIORITY PRESS - 88th Canadian Paediatric Society Annual Conference
Advances in Paediatric Immunization: Targeting the Last Remaining Serogroup Towards Complete Meningococcal Disease Control
Québec City, Québec / June 15-18, 2011
Québec City - Five serogroups cause the majority of clinical meningococcal disease worldwide; 4 of these are preventable through both monovalent and quadrivalent vaccination. Meningococcal disease researchers have long sought to...
PRIORITY PRESS - 88th Canadian Paediatric Society Annual Conference
Daily Asthma Controller Therapy and a Written Action Plan: Keys to Good Asthma Management
Québec City, Québec / June 15-18, 2011
Québec City - Asthma is a chronic, underlying inflammatory condition that requires daily controller therapy to maintain symptomatic control. Unfortunately, it is often treated as an episodic illness, with parents citing fear of side...
PRIORITY PRESS - 16th Congress of the European Hematology Association (EHA)
Improving Response Rates and Duration in Patients with Multiple Myeloma
London, UK / June 9-12, 2011
London - Initially studied in the treatment of multiple myeloma patients in relapsed and refractory settings, proteasome inhibitor-based regimens have now been shown to improve outcomes in transplant-eligible and -ineligible patients with...
MEDICAL FRONTIERS - 16th Congress of the European Hematology Association (EHA)
Improving Responses to First-line Treatment in Chronic Myeloid Leukemia
London, United Kingdom / June 9-12, 2011
London - With the introduction of the first tyrosine kinase inhibitor (TKI) 10 years ago, treatment of chronic myeloid leukemia (CML) was revolutionized. Imatinib became the standard of care and in follow-up analysis of clinical trials it...
MEDICAL FRONTIERS - 29th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID)
Extended Protection Against Serious Infections: Meningococcal B Disease and Influenza
The Hague, The Netherlands / June 7-11, 2011
Medical Editor: Dr. Julie Frère, Montreal, Québec Whether it manifests as sepsis or meningitis, invasive meningococcal disease (IMD) is well known to physicians who treat children. Recognizing the infection before it becomes...
PRIORITY PRESS - 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
New Directions in Castration-resistant Prostate Cancer Management
Chicago, Illinois / June 3-7, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Québec Data from 5 phase III studies for the treatment of castration-resistant prostate cancer (CRPC) were presented during the 2011 ASCO annual meeting. Some...
MEDICAL FRONTIERS - 12th Annual European Congress of Rheumatology (EULAR)
Expanding Research in Intracellular Signalling: Promising Data in Rheumatoid Arthritis with Small-molecule Inhibitors
London, UK / May 25-28, 2011
Chief Medical Editor: Dr. Léna Coïc, Montréal, Québec The biologic agents first introduced for the treatment of rheumatoid arthritis (RA) more than a decade ago have provided unprecedented control in patients...
MEDICAL FRONTIERS - 12th Annual European Congress of Rheumatology (EULAR)
Preventing Rheumatoid Arthritis Progression: A Recent Demonstration of the Efficacy of Biologics
London, UK / May 25-28, 2011
London - Relative to disease-modifying antirheumatic drugs (DMARDs), the targeted biologic agents have demonstrated remarkable efficacy, often achieving full restoration of function in patients with refractory and disabling symptoms. It has...